Skip to main content

Moleculin Biotech, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

MBRX$8.70-0.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Form 10-Q

Table of Contents

Page
PART I – FINANCIAL INFORMATION3
Item 1.Financial Statements (Unaudited)3
Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026 and 20254
Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026 and 20255
Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2026 and 20256
Notes to Condensed Consolidated Financial Statements7
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations13
Item 3.Quantitative and Qualitative Disclosures About Market Risk17
Item 4.Controls and Procedures17
PART II – OTHER INFORMATION17
Item 1.Legal Proceedings17
Item 1A.Risk Factors17
Item 2.Unregistered sales of Equity Securities and Uses of Proceeds18
Item 3.Defaults Upon Senior Securities18
Item 4.Mine Safety Disclosures18
Item 5.Other Information18
Item 6.Exhibits19
Signatures20
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.